Add office photos
Premium Employer
Mankind Pharma
3.9
based on 2.5k Reviews
Video summary
Company Overview
Associated Companies
Company Locations
Working at Mankind Pharma
Company Summary
Mankind Pharma is one of the Indian leading pharmaceutical companies and changes the pharma industry. They provide world-class medications at affordable prices.
Overall Rating
3.9/5
based on 2.5k reviews
On-Par with
industry average
Highly rated for
Salary
Work Policy
Work from office
71% employees reported
Monday to Saturday
67% employees reported
Strict timing
53% employees reported
Within city
40% employees reported
View detailed work policy
Top Employees Benefits
Job/Soft skill training
159 employees reported
Health insurance
131 employees reported
Office cab/shuttle
57 employees reported
Cafeteria
42 employees reported
View all benefits
About Mankind Pharma
Founded in1995 (30 yrs old)
India Employee Count10k-50k
Global Employee Count10k-50k
India HeadquartersNew Delhi, Delhi, India
Office Locations
Websitemankindpharma.com
Primary Industry
Other Industries
Are you managing Mankind Pharma's employer brand? To edit company information,
claim this page for free
View in video summary
Mankind Pharma, one of the top 5 leading pharmaceutical companies in India, started its journey in 1995. Today, we have an employee base of over 17,000 and are racing towards $1 Billion. At Mankind, we aspire to aid the community in leading a healthy life by formulating, developing, commercializing, and delivering affordable and accessible medicines that satisfy urgent medical needs. We take great pride in the success of our products ranging from Pharma, OTC, and FMCG brands like Manforce Condoms, Manforce Tablets, Manforce Staylong Gel, Unwanted 72, Prega News, Gas-O-Fast, Kaloree 1, Kabzend, Acne Star Gel, and many others. Our operations are in 34 overseas destinations across Asia, Africa, South-East Asia, Gulf countries, and CIS countries.
Mission: To be able to provide cost-effective, innovation based superior quality pharmaceutical products that improve the lives of the patients.
Vision: To be an innovative and research focused healthcare company, most admired for its Quality, Affordability and Accessibility.
Managing your company's employer brand?
Claim this Company Page for FREE
Mankind Pharma Ratings
based on 2.5k reviews
Overall Rating
3.9/5
How AmbitionBox ratings work?
5
1.3k
4
559
3
285
2
142
1
231
Category Ratings
3.8
Salary
3.7
Skill development
3.6
Company culture
3.6
Job security
3.6
Work-life balance
3.5
Promotions
3.5
Work satisfaction
Mankind Pharma is rated 3.9 out of 5 stars on AmbitionBox, based on 2.5k company reviews.This rating reflects an average employee experience, indicating moderate satisfaction with the company’s work culture, benefits, and career growth opportunities. AmbitionBox gathers authentic employee reviews and ratings, making it a trusted platform for job seekers and employees in India.
Read more
Gender Based Ratings at Mankind Pharma
based on 2.3k reviews
3.7
Rated by 131 Women
Rated 3.7 for Job security and 3.5 for Work-life balance
3.9
Rated by 2.2k Men
Rated 3.9 for Salary and 3.7 for Skill development
Work Policy at Mankind Pharma
based on 353 reviews in last 6 months
Work from office
71%
Hybrid
23%
Permanent work from home
6%
Mankind Pharma Reviews
Top mentions in Mankind Pharma Reviews
+ 5 more
Compare Mankind Pharma with Similar Companies
Change Company | Change Company | Change Company | ||
|---|---|---|---|---|
Overall Rating | 3.9/5 based on 2.5k reviews | 4.0/5 based on 5.8k reviews | 4.1/5 based on 6.9k reviews | 5.0/5 based on 1 reviews |
Highly Rated for | Salary | Salary Skill development Job security | Skill development Salary Work-life balance | Skill development Work-life balance Salary |
Critically Rated for | No critically rated category | No critically rated category | No critically rated category | No critically rated category |
Primary Work Policy | Work from office 71% employees reported | Work from office 82% employees reported | Work from office 73% employees reported | - |
Rating by Women Employees | 3.7 Good rated by 131 women | 4.0 Good rated by 446 women | 4.0 Good rated by 688 women | - no rating available |
Rating by Men Employees | 3.9 Good rated by 2.2k men | 4.0 Good rated by 5.1k men | 4.1 Good rated by 5.9k men | - no rating available |
Job security | 3.6 Good | 3.8 Good | 3.7 Good | 4.0 Good |
View more
Mankind Pharma Salaries
Mankind Pharma salaries have received with an average score of 3.8 out of 5 by 2.5k employees.
Officer
(359 salaries)
Unlock
₹2.4 L/yr - ₹6.5 L/yr
Research Associate
(328 salaries)
Unlock
₹3 L/yr - ₹6.3 L/yr
Research Scientist
(279 salaries)
Unlock
₹3.6 L/yr - ₹10.5 L/yr
Senior Officer
(275 salaries)
Unlock
₹3.3 L/yr - ₹8.1 L/yr
Medical Representative
(223 salaries)
Unlock
₹1.4 L/yr - ₹6.5 L/yr
Area Sales Manager
(173 salaries)
Unlock
₹4.8 L/yr - ₹11 L/yr
Deputy Manager
(146 salaries)
Unlock
₹6 L/yr - ₹20.5 L/yr
Senior Research Scientist
(140 salaries)
Unlock
₹6 L/yr - ₹15.7 L/yr
Regional Sales Manager
(90 salaries)
Unlock
₹7.6 L/yr - ₹24 L/yr
Area Manager
(74 salaries)
Unlock
₹4.2 L/yr - ₹10 L/yr
Mankind Pharma Interview Questions
Interview questions by designation
Top Mankind Pharma interview questions and answers
Get interview-ready with top interview questions
Mankind Pharma Jobs
Popular Skills Mankind Pharma Hires for
Current Openings
Mankind Pharma News
View all
Mankind Pharma Launches Generic Version Of Empagliflozin Diabetes Medication
- Mankind Pharma has launched a generic version of Empagliflozin, a diabetes medication, in India following the expiration of Boehringer Ingelheim's patent for the drug.
- The generic version is available under the brand names Empaglyde, Empagreat, and Dynaduo, in various strengths (10 mg to 25 mg).
- The launch aims to increase accessibility and affordability, with prices starting at Rs 5.49 for the 10 mg variant and Rs 9.90 for the 25 mg variant.
- Other companies, including Glenmark and Alkem Laboratories, have also introduced generic versions of Empagliflozin in India.
Bloomberg Quint | 12 Mar, 2025
Share Market Highlights 25 February 2025: Sensex, Nifty end flat with a positive bias; Bharti Airtel, M&M lead gains
- Zaggle, a Hyderabad-based software-as-a-service company, will provide comprehensive services for the citizen card and implement the Visitor Management System in GIFT City.
- GIFTCL and Zaggle have entered into a five-year agreement with possible extensions to enhance security and streamline access within GIFT City.
- Axis Finance is undergoing a strategic review with a potential valuation of $900 million to $1 billion, as disclosed by unidentified sources.
- Companies like Max Healthcare, Mankind, and Ashok Leyland witnessed stock gains, whereas Petronet LNG and Delhivery faced losses.
- Tata Capital, with an AUM of ₹1,58,479 crore as of March 2024, is issuing shares worth ₹1,504 crore on a rights basis, with an IPO size expected to be around ₹15,000 crore.
- Camlin Fine Sciences acquires a majority stake in French natural ingredients company Vinpai S.A. to enhance its product range and capabilities.
- Dodo Payments secures $1.1 million in a pre-seed funding round led by Antler, 9Unicorns, and Venture Catalysts, aimed at simplifying international payments for businesses.
- AI adoption in energy companies for predictive maintenance and personalized customer engagement is growing, with GenAI playing a crucial role in enhancing core operations.
- A new environmentally friendly 3-wheeled vehicle, MOBILI SWAP, aims to reduce operating costs and improve efficiency in the transport sector with interchangeable batteries.
- Former President Ranjan Bargotra re-joins Crayons Advertising as Executive Director, bringing strategic expansion plans and extensive industry experience.
HinduBusinessLine | 25 Feb, 2025
Pet Food Brand Dogsee Chew Raises $8 Mn To Scale Global Operations
- Bengaluru-based pet food brand Dogsee Chew has raised $8 million in a Series B funding round led by Ektha.com, with participation from Shivanssh Holdings and Poddar Family office.
- The funding will be used to expand manufacturing capabilities and establish a stronger presence in international markets, particularly the US and Canada.
- Dogsee Chew is known for its vegetarian treats made from Himalayan cheese and aims to become the largest Himalayan chew manufacturer globally.
- The company has already secured previous investments from Mankind Pharma, Sixth Sense Ventures, and has a strong global presence in over 30 countries.
Inc42 | 20 Feb, 2025
MSCI Rejig: Hyundai India Only Addition In February Review; IndusInd Bank, Zomato Weights To Rise
- Hyundai Motor India, IndusInd Bank, Zomato, Varun Beverages, and Mankind Pharma will have increased weightage in the February MSCI review.
- India's weight in MSCI Global Standard Indexes will rise to 19% from the current 18.8% after the quarterly rejig.
- HDFC Bank holds the highest weightage among Indian stocks in MSCI indexes, followed by Reliance Industries, ICICI Bank, Infosys, and Bharti Airtel.
- MSCI added 19 Indian small-cap stocks and removed an equal number from its indices.
Bloomberg Quint | 12 Feb, 2025
Mankind Pharma Approves Sale Of Entire Stake In Wholly Owned Mahananda Spa And Resorts To Chalet Hotels
- Mankind Pharma has approved the sale of its entire stake in Mahananda Spa and Resorts.
- The sale is to Chalet Hotels for an enterprise value of Rs 530 crore.
- The proceeds will be used to retire part of Mankind Pharma's debts.
- The transaction is expected to be completed by February 28.
Bloomberg Quint | 10 Feb, 2025
Tech Query: What is the outlook for Infosys, Barbeque-Nation Hospitality, Mankind Pharma, Happiest Minds Technologies?
- Infosys: The stock is in an uptrend and has been consolidating between ₹1,700 and ₹2,000. Strong support is at ₹1,800-₹1,700. If above support, the outlook remains bullish and a break above ₹2,000 could take the stock to ₹2,300-₹2,400.
- Barbeque-Nation Hospitality: The stock is in a downtrend and has fallen significantly. Resistance is at ₹385 and there is a risk of the stock declining to ₹120. Accumulating at current levels is not advisable. Exit and accept the loss.
- Mankind Pharma: The stock is in a corrective fall and can touch ₹2,250, after which a rally could take it to ₹3,200 over the next couple of years. Selling 20% of the holding and buying at ₹2,300 with a stop-loss at ₹2,140 is recommended.
- Happiest Minds Technologies: The stock is in a downtrend and could fall to ₹610-₹600. Holding on to the stock is not advisable. Consider reinvesting in another stock, such as Mankind Pharma.
HinduBusinessLine | 8 Feb, 2025
Buy, Sell Or Hold: Zomato, RVNL, IRFC, Mankind Pharma, IOC, Bajaj Housing Finance — Ask Profit
- Analysts shared insights on share prices of Zen Technologies, Mankind Pharma, and Natco Pharma.
- RVNL (CMP: Rs 427.65) was advised to hold with strong support at Rs 410–415 levels.
- IRFC (CMP: Rs 141.73) was recommended to hold for one to two weeks with an upside target of 5–8% and a potential to reach Rs 155.
- Mankind Pharma (CMP: Rs 2,477.5) was suggested as a buy with a long-term target of Rs 2,700 in one year.
- Bajaj Housing Finance (CMP: Rs 1,115.87) was advised as a buy, as the numbers were good and there is a good upside potential.
- Zomato (CMP: Rs 222.50) was recommended as a sell, given the high volatility and overall downward trend in the stock.
- Natco Pharma (CMP: Rs 1,171.00) was advised to hold with a target of Rs 1,450 in six-eight months.
- Indian Oil Corp (CMP: Rs 123.64) was suggested to hold with a target of Rs 150–160 in six to 12 months.
- Zen Technologies (CMP: Rs 1,695.30) was recommended to hold for one to two years as a good pick in the long term.
Bloomberg Quint | 29 Jan, 2025
.jpg?w=1200&auto=format%2Ccompress&ogImage=true)
Mankind Pharma, Innovent Biologics Partner To Launch Sintilimab In India
- Mankind Pharma and Innovent Biologics have partnered to launch the immunotherapy drug Sintilimab in the Indian market.
- The collaboration aims to address the critical challenges in cancer treatment and improve patient access to innovative therapeutic options in the region.
- Sintilimab is co-developed by Innovent and Eli Lilly and is marketed as TYVYT in China.
- Mankind Pharma will file for regulatory approval in India and conduct a phase 3 clinical trial to obtain approval for Sintilimab in the country.
Bloomberg Quint | 26 Dec, 2024
Mankind Pharma, Innovent Biologics partner to bring immunotherapy drug sintilimab to India
- Mankind Pharma has partnered with Innovent Biologics to bring immunotherapy drug sintilimab to India.
- Sintilimab, marketed as Tyvyt, is a monoclonal antibody that blocks the PD-1/PD-L1 pathway, reactivating T-cells to target and eliminate cancer cells.
- The drug has shown efficacy and safety across multiple cancer types and is already approved for eight indications in China.
- Mankind Pharma will have exclusive rights to market and distribute sintilimab in India, while Innovent will oversee manufacturing and supply.
HinduBusinessLine | 26 Dec, 2024
Today Startup News 17 December 2024 From The Indian Startup Ecosystem
- Mili, an AI meeting assistant for wealth management platform, secures $2 million in seed funding led by Chiratae and BoldCap.
- Crown Veterinary Services (Crown Vet), a healthtech startup, raises undisclosed funds from Mars Veterinary Health.
- Mankind Pharma launches Rs 3,000 crore QIP to fund Bharat Serums acquisition.
- The Competition Commission of India (CCI) approves KKR's stake acquisition in Rebel Foods.
VIE Stories | 17 Dec, 2024
Powered by
Mankind Pharma Subsidiaries
Pathkind Diagnostics Private Limited
4.0
• 451 reviews
Report error
Mankind Pharma Offices
Compare Mankind Pharma with
Torrent Pharmaceuticals
3.9
Lupin
4.2
Zydus Lifesciences
4.1
Glenmark Pharmaceuticals
3.9
Biocon Limited
3.9
Aurobindo Pharma
4.0
DIVI'S Laboratories
3.7
Dr. Reddy's
4.0
Intas Pharmaceuticals
4.1
Hetero
3.8
Viatris
4.2
Alkem Laboratories
3.9
Ipca Laboratories
3.9
MSN Laboratories
3.7
Akums Drugs & Pharmaceuticals Limited
4.4
Pfizer
4.0
Piramal Group
3.9
Fresenius Kabi
4.2
Novo Nordisk
4.1
Teva Pharmaceuticals
3.9
Edit your company information by claiming this page
Contribute & help others!
You can choose to be anonymous
Companies Similar to Mankind Pharma
Sun Pharmaceutical Industries
Healthcare / Pharma, Manufacturing, Analytics & KPO, Pharma
4.0
• 5.8k reviews
Cipla
Manufacturing, Pharma
4.1
• 6.9k reviews
DRJ & CO
Architecture & Interior Design
5.0
• 1 reviews
Torrent Pharmaceuticals
Pharma
3.9
• 2.5k reviews
Lupin
Biotech & Life sciences, Manufacturing, Pharma
4.2
• 6.1k reviews
Zydus Lifesciences
Biotech & Life sciences, Pharma
4.1
• 6k reviews
Glenmark Pharmaceuticals
Pharma
3.9
• 2.9k reviews
Biocon Limited
Biotech & Life sciences, Biotechnology
3.9
• 1.9k reviews
Aurobindo Pharma
Healthcare / Pharma, Biotechnology, Pharma
4.0
• 4.8k reviews
DIVI'S Laboratories
Pharma
3.7
• 1.4k reviews
Dr. Reddy's
Clinical Research, Pharma
4.0
• 6.8k reviews
Intas Pharmaceuticals
Biotech & Life sciences, Pharma
4.1
• 3.5k reviews
Mankind Pharma FAQs
When was Mankind Pharma founded?
Mankind Pharma was founded in 1995. The company has been operating for 30 years primarily in the Pharma sector.
Where is the Mankind Pharma headquarters located?
Mankind Pharma is headquartered in New Delhi, Delhi. It operates in 2 cities such as New Delhi, Gurgaon / Gurugram. To explore all the office locations, visit Mankind Pharma locations.
How many employees does Mankind Pharma have in India?
Mankind Pharma currently has more than 19,000+ employees in India. Marketing & Communication department appears to have the highest employee count in Mankind Pharma based on the number of reviews submitted on AmbitionBox.
Does Mankind Pharma have good work-life balance?
Mankind Pharma has a Work-Life Balance Rating of 3.6 out of 5 based on 2,400+ employee reviews on AmbitionBox. 73% employees rated Mankind Pharma 4 or above, while 27% employees rated it 3 or below on work-life balance. This indicates that the majority of employees feel a generally balanced work-life experience, with some opportunities for improvement based on the feedback. We encourage you to read Mankind Pharma work-life balance reviews for more details
Is Mankind Pharma good for career growth?
Career growth at Mankind Pharma is rated fairly well, with a promotions and appraisal rating of 3.5. 73% employees rated Mankind Pharma 4 or above, while 27% employees rated it 3 or below on promotions/appraisal. Though the sentiment is mixed for career growth, majority employees have rated it positively. We recommend reading Mankind Pharma promotions/appraisals reviews for more detailed insights.
What are the pros of working in Mankind Pharma?
Working at Mankind Pharma offers several advantages that make it an appealing place for employees. The company is highly rated for salary & benefits, based on 2,400+ employee reviews on AmbitionBox.
Stay ahead in your career. Get AmbitionBox app
Helping over 1 Crore job seekers every month in choosing their right fit company
75 Lakh+
Reviews
5 Lakh+
Interviews
4 Crore+
Salaries
1 Cr+
Users/Month
Contribute to help millions
Get AmbitionBox app
Made with ❤️ in India. Trademarks belong to their respective owners. All rights reserved © 2024 Info Edge (India) Ltd.
Follow us
